Mergers and acquisitions (M&A) in healthcare looks set to be strong again this year, Goldman Sachs (GS) said on Monday, following deal announcements from pharmaceutical giants Shire (London Stock Exchange: SHP-GB) and Roche Holdings (Swiss Exchange: ROG-CH).
And the co-CEO of Goldman Sachs International, Richard Gnodde, also said that energy-a quieter sector for activity last year-was set to shine in 2015.
Over the weekend, Shire (London Stock Exchange: SHP-GB) announced it would buy the U.S.'s NPS Pharmaceuticals for $5.2 billion . This was Shire's first big move since a tax inversion deal with AbbVie (ABBV) fell through last year, and shares jumped in early trade on Monday before paring gains.
Goldman Sachs acted as a financial adviser to NPS Pharma (NPSP) regarding the deal, alongside Leerink Partners.
"It was terrific to see the market react on the Shire side in the way it did, with the stock price going up, which shows the market is really still supportive of M&A," Gnodde, who's also co-head of investment banking at Goldman, said on Monday at the bank's strategy conference in London.
"We would expect M&A broadly to continue. We think healthcare will be a big player; telecoms, again, will see a lot of activity. But then potentially even some of the sectors that were quieter last year (such as) energy-there has been so much change in the energy space, that will likely lead to some activity too."
Read More Oil's new normal is lower for longer: Goldman
M&A volumes rebounded in 2014, rising 26 percent on the year to $3.60 trillion, according to financial software provider Dealogic. It marked the third-highest volume on record, behind 2007 ($4.62 trillion) and 2006 ($3.91 trillion).
Healthcare was the most targeted industry for M&A in 2014, with major deals including Actavis (ACT)'s $65.70 billion bid for Allergan (AGN), and Medtronic (MDT)'s $46.8 billion offer for Covidien (COV).
Shire's weekend announcement saw stockbroking firm Panmure Gordon reiterate its "buy" recommendation on the Irish drug major on Monday.
Read More Big deals, data kick off JPMorgan health conference
In other news from the sector, Switzerland's Roche made a majority bid for Massachusetts-based Foundation Medicine -to which Goldman Sachs is also acting as an adviser.
Roche said it would tender for 15.6 million shares in the genomic and molecular analysis firm at $50 a share-more than twice their value on Friday-and said it would additionally invest $250 million by acquiring 5 million newly issued shares at $50 per share.
Roche shares traded around 2 percent higher on Monday after the news.